Related Experiment Video
Updated: Sep 4, 2025
04:09
Author Spotlight: Gut Microbiome-Lung Tissue Communication Through Short-Chain Fatty Acid Analysis
Published on: June 21, 2024
1.8K
Exogenous Short Chain Fatty Acid Effects in APP/PS1 Mice
Diana J Zajac1, Benjamin C Shaw1, David J Braun2
1Department of Physiology and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, United States.
Frontiers in Neuroscience
|July 21, 2022
Summary
Short chain fatty acids (SCFAs) altered the gut microbiome in Alzheimer's Disease (AD) mice but did not impact memory, brain inflammation, or amyloid plaques. Further research is needed to understand SCFA roles in AD.
Area of Science:
- Microbiology
- Neuroscience
- Gastroenterology
Background:
- The gut microbiome influences brain health, with short chain fatty acids (SCFAs) potentially mediating these effects.
- Alzheimer's Disease (AD) pathogenesis involves complex interactions, including potential gut-brain axis dysregulation.
Purpose of the Study:
- To investigate the impact of SCFA administration on the gut microbiome and AD-related neuropathology in a mouse model.
- To assess if SCFA treatment affects spatial memory, astrocyte activation, and amyloid burden in APPswe/PSEN1dE9 mice.
Main Methods:
- APPswe/PSEN1dE9 mice received SCFA-treated water or saline from 5 to 10 months of age.
- Evaluations included microbiome profiling, radial arm water maze for spatial memory, Gfap expression for astrocyte activation, and amyloid burden assessment.
Main Results:
- SCFA treatment increased gut microbial alpha-diversity and altered bacterial composition, favoring SCFA-producing bacteria.
- No significant effects were observed in spatial memory, cortical/hippocampal astrocyte activation, or amyloid plaque load (soluble/insoluble).
Conclusions:
- SCFA administration modulates the gut microbiome composition but does not ameliorate cognitive deficits or neuropathology in this AD mouse model.
- These findings suggest that under conventional microbiome conditions, SCFAs alone may not be sufficient to alter AD progression in APP/PS1 mice.
